Size, Share & Industry Analysis, By Imaging Modality (Echocardiography, Cardiac CT, Cardiac MRI, X-ray Angiography and Fluoroscopy), By Clinical Application (Valvular Disease Assessment, Congenital and Septal Defects, Left Atrial Appendage Procedures, Post-implant Surveillance), By End User (Hospitals and Heart Valve Centres, Independent Cardiac Imaging Centres, Ambulatory Specialty Facilities), By Product Layer (Imaging Hardware and Consoles, Planning and Quantification Software, Imaging Catheters and Contrast Consumables), and Regional Forecast, 2026-2034
Explore the report section by section.
The global Structural Heart Imaging (SHI) Market reached USD 12.7 billion in 2025 and is estimated at USD 13.6 billion in 2026. Revenue is projected at USD 23.1 billion by 2034, representing a 6.9% CAGR from 2026 to 2034.
The structural heart imaging revenue boundary includes cardiac ultrasound consoles and dedicated probes, CT and MRI equipment allocated to structural-heart examinations, procedure-guidance imaging systems, intracardiac imaging catheters, and licensed planning or quantification software. Standalone valve implants, coronary stents, operating-room services and unrelated general radiology are excluded. The forecast reflects supplier revenue for the attributable imaging product and software portion rather than the entire price of a valve intervention or hospital admission.
In the 2026 PREVUE-VALVE study of 3,000 older Americans, investigators measured an 8.2% weighted prevalence of at least moderate valvular disease, with 18.4% meeting the broader clinically significant definition. Screening and surveillance generate recurring echocardiography demand, while more complex anatomy requires CT or transesophageal imaging before intervention. In August 2025, European cardiology societies updated their valvular guidelines to emphasize Heart Teams, advanced imaging and assessment of multiple valve lesions.
Recent product introductions broaden the range of 3D imaging and planning workflows used by heart teams. GE HealthCare launched Vivid Pioneer in August 2025 with 2D and 4D cardiovascular ultrasound, automated Doppler and FDA clearance. Philips introduced VeriSight Pro 3D intracardiac echocardiography in Europe in May 2025, then announced FDA clearance for EchoNavigator DeviceGuide in March 2026. These systems address different procedural tasks, so a hospital can buy both a diagnostic scanner and dedicated catheter-lab guidance tools.
Cardiac CT has become integral to transcatheter aortic valve replacement planning because annular dimensions, coronary heights and vascular access must be evaluated before device selection. The American College of Cardiology highlighted a June 2025 multisociety consensus on CT evaluation of prosthetic valves, while the U.S. Medicare program updated TAVR coverage in September 2026. Capital purchasing remains sensitive to hospital budgets, radiation protocols, contrast restrictions and the availability of trained imaging specialists.
Source: PREVUE-VALVE study; ESC 2025 guidance; GE Vivid Pioneer launch; CMS TAVR coverage.
Revenue comprises structural-heart-specific imaging hardware, consumable imaging catheters and contrast products, and attributable software licences for valve and septal disease evaluation, intervention guidance and follow-up.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million/billion |
| By Imaging Modality | Echocardiography; Cardiac CT; Cardiac MRI; X-ray Angiography and Fluoroscopy |
| By Clinical Application | Valvular Disease Assessment; Congenital and Septal Defects; Left Atrial Appendage Procedures; Post-implant Surveillance |
| By End User | Hospitals and Heart Valve Centres; Independent Cardiac Imaging Centres; Ambulatory Specialty Facilities |
| By Product Layer | Imaging Hardware and Consoles; Planning and Quantification Software; Imaging Catheters and Contrast Consumables |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; Germany; United Kingdom; Italy; Japan; China; India; Brazil; United Arab Emirates |
| Key Market Players | GE HealthCare; Royal Philips; Siemens Healthineers; Canon Medical Systems; FUJIFILM Healthcare; Mindray; Esaote; Pie Medical Imaging; Circle Cardiovascular Imaging; Materialise; Bracco Imaging; Edwards Lifesciences |
Each scanner or imaging system is allocated only for its structural-heart use, so a multipurpose CT installation is not counted at its entire price when the unit is used across oncology and other departments. Intracardiac echocardiography catheters are counted as imaging consumables, while TAVR valves, mitral clips and left atrial appendage closure implants are excluded. Imaging analysis software is counted separately from the physical scanner only where sold under a distinct commercial licence.
Imaging modality classifies each revenue item by the technology that generates or displays the images; application classifies the clinical indication, end user identifies the purchasing care setting, and product layer distinguishes hardware, software and consumables. The four dimensions are independent views of the same 2025 total, with mutually exclusive categories within each dimension. All regional and segment shares are scenario allocations rather than audited vendor sales.
Drivers Impact Analysis*
| Market Drivers | Impact Rank | CAGR Contribution (%) | 2026–2028 | 2029–2031 | 2032–2034 |
|---|---|---|---|---|---|
| Higher valve-disease detection in older adults | High | +2.70% | High | High | High |
| Growth of transcatheter valve procedures | High | +2.30% | High | High | High |
| CT-based valve planning and redo interventions | Medium-High | +1.65% | Medium | High | High |
| Intracardiac 3D imaging and fusion guidance | Medium | +1.20% | Medium | High | High |
| Others (AI quantification, surveillance, specialist training) | Low | +0.55% | Medium | Medium | High |
Restraints Impact Analysis*
| Market Restraints | Impact Rank | CAGR Contribution (%) | 2026–2028 | 2029–2031 | 2032–2034 |
|---|---|---|---|---|---|
| Hospital equipment budgets and scanner costs | High | -0.70% | High | Medium | Medium |
| Shortage of trained structural imaging operators | Medium-High | -0.45% | High | High | Medium |
| Radiation, contrast and reimbursement restrictions | Medium | -0.20% | Medium | Medium | Medium |
| Others (maintenance, interoperability, procurement delays) | Low | -0.15% | Medium | Low | Low |
*CAGR contribution shows the percentage points each factor adds to or removes from the 6.9% CAGR for 2026–2034; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.
The PREVUE-VALVE investigators assessed 3,000 U.S. adults aged 65–85 and found at least moderate valve disease in 8.2%. That prevalence creates repeat diagnostic demand, since clinicians use transthoracic echocardiography to evaluate gradients, regurgitation and ventricular response before choosing surveillance or intervention. An Italian registry published in 2025 found 22.5% moderate or severe valvulopathy among participants aged 75 and older. Growth in older patient cohorts therefore supports scanner replacement, dedicated valve-clinic staffing and more frequent imaging follow-up.
Pre-procedure CT establishes aortic annular dimensions, coronary obstruction risk and access anatomy before valve selection. The American College of Cardiology described a 2025 expert framework covering echo, CT, MRI and PET for evaluating transcatheter valve failure and repeat interventions. In a separate CT simulation study of 913 post-TAVR scans, anatomical measurements informed redo-TAV risk assessment. These documented planning steps generate demand for licensed reconstruction and measurement software alongside conventional scanner capacity, particularly in high-volume interventional centers.
Philips launched VeriSight Pro 3D ICE in Europe in May 2025, enabling real-time intracardiac views during selected valve and left atrial appendage procedures. Its catheter-based approach can reduce reliance on general anesthesia when suitable for the case. Philips received FDA clearance in March 2026 for EchoNavigator R5.0 with DeviceGuide, combining live ultrasound and fluoroscopy with device tracking for specified mitral repair procedures. Procurement increasingly weighs image quality, compatibility with cath-lab platforms and the cost of single-use imaging accessories.
Advanced CT, 4D echocardiography and hybrid cath-lab systems require substantial equipment investment and qualified acquisition and interpretation teams. The 2025 European valvular guidelines emphasize experienced Heart Valve Centres for complex care, reflecting the dependence of imaging quality on specialist workflows. Smaller hospitals may refer complex procedures to regional centers rather than purchase every modality. Radiation exposure, iodinated contrast risks, device maintenance and software subscription expenses further constrain adoption when procedure volumes are too low to support fixed costs.
The U.S. Centers for Medicare and Medicaid Services revised the TAVR National Coverage Determination on 10 September 2026, modifying coverage pathways for asymptomatic severe aortic stenosis and evidence-development requirements. The change affects which patients can receive covered valve procedures and therefore their associated pre-intervention imaging. In contrast, routine echo and CT reimbursement remains governed by separate medical-necessity and coding rules. Suppliers must demonstrate workflow or diagnostic value rather than assume that every additional valve intervention automatically produces a new scanner purchase.
Sources: PREVUE-VALVE (2026); ESC/EACTS valvular guidance (2025); American College of Cardiology CT consensus (2025); Philips product clearances (2025–2026); CMS TAVR coverage decision (2026).
GE HealthCare reported that its Vivid Pioneer platform uses AI Cardiac Auto Doppler and automated chamber quantification, with product clearance announced in August 2025. Reproducible measurements matter in structural disease because serial examinations must distinguish progression from reader variability. Automation also helps departments manage a limited pool of experienced sonographers. However, measurement algorithms require clinician review when anatomy is distorted by prostheses, calcification or congenital defects, so hospitals are purchasing workflow tools rather than replacing interpretation expertise with unattended image analysis.
Canon Medical offers CT TAVR Planning Assist with automated measurements, while Siemens Healthineers provides syngo.via workflows for aortic valve and annular evaluation. Materialise combined its cardiac 3D planning tools with FEops simulation after a July 2024 acquisition, enabling patient-specific procedural scenarios. Software that links CT segmentation to implant choice can be purchased by heart teams independently of a scanner replacement. Adoption is strongest where interventionalists and imaging specialists share standardized protocols and structured reporting across repeated procedures.
Philips announced U.S. clearance for EchoNavigator DeviceGuide in March 2026, integrating live echocardiography with Azurion fluoroscopy for selected mitral repair workflows. In complex leaflet grasping, device orientation and imaging-plane selection require coordination between interventionalists and echocardiographers. Fused visualization can reduce repeated manual alignment and support clearer procedural communication. Broader use depends on device-specific approvals, installed cath-lab compatibility and demonstrated clinical benefits, so adoption is likely to be phased by intervention type rather than uniform across all valve procedures.
The May 2025 European introduction of Philips VeriSight Pro brought a 3D intracardiac catheter to structural interventions already using transesophageal imaging. Catheter-based visualization offers a procedural alternative for patients in whom general anesthesia is undesirable, though catheter cost and vascular access must be considered. Imaging specialists also need new acquisition skills, including steering the intracardiac probe and recognizing orientation differences from conventional TEE. Hospitals with high volumes of appendage closure and valve repair have stronger incentives to establish dedicated ICE workflows.
Bracco announced U.S. FDA clearance and Health Canada authorization in August 2026 for VueJect, a dedicated ultrasound contrast delivery system intended to support cardiology imaging. The company already markets Lumason or SonoVue ultrasound-enhancing agents, used for ventricular chamber opacification under approved indications. Standardized contrast delivery can improve consistency where conventional echocardiographic borders are difficult to visualize. The effect on structural-heart imaging spending remains bounded because contrast enhancement is used selectively and does not replace 3D valve geometry from CT or transesophageal studies.
Structural heart imaging purchases are allocated to four mutually exclusive technologies: echocardiography, cardiac CT, cardiac MRI, and X-ray angiography or fluoroscopy. Different modalities answer distinct clinical questions, so complex cases may use several examinations without counting the same product twice.
Echocardiography represented an estimated ~48% of 2025 revenue because transthoracic and transesophageal imaging are routinely used for valve assessment, hemodynamics and real-time intervention guidance. GE HealthCare Vivid Pioneer and Philips EPIQ CVx support 2D and 3D or 4D acquisitions, while intracardiac probes add a specialized procedural option. Repeat examinations create continuing demand for probes, service and replacements.
Cardiac CT is used to size valve annuli, assess calcification, examine access vessels and anticipate coronary obstruction during TAVR. Siemens syngo.via, Canon TAVR Planning Assist and 3mensio translate CT data into planning measurements. CT capital purchases are less frequent than echo examinations, but software and high-resolution scanner upgrades create value in structural heart centers.
Cardiac MRI contributes ventricular volumes, flow quantification and tissue characterization when echo findings are incomplete or multiple lesions complicate treatment selection. Circle Cardiovascular Imaging provides cvi42 tools for MRI analysis, while the European imaging consensus recognizes multimodality assessment. MRI has longer examination times and limited availability in some hospitals, restricting its share despite strong clinical utility.
Fluoroscopic systems show catheters and implanted devices during valve repair and replacement. Philips Azurion integrates with EchoNavigator, combining anatomical ultrasound views with device positions. The modality depends on radiation protection, catheter-lab investment and operator expertise; its revenue is allocated to imaging systems and guidance tools rather than the value of the implanted device.
By 2034, cardiac CT and software-assisted fluoroscopic fusion should gain importance in procedural planning, while echocardiography remains the principal recurring examination modality for initial assessment and surveillance.
Four application groups classify the principal clinical purpose of each imaging sale: valve disease assessment, congenital or septal defects, left atrial appendage procedures, and post-implant surveillance. Each use case is assigned once according to its dominant indication.
Valvular Disease Assessment represented an estimated ~56% of 2025 revenue. Aortic stenosis, mitral regurgitation and tricuspid disease require assessment of severity, anatomy and ventricular response. The 2025 ESC/EACTS guidance strengthened the role of advanced echo, CT and MRI in choosing intervention timing, and procedure growth supports new planning licences.
Congenital defects and septal abnormalities require detailed spatial imaging of chambers, shunts and adjacent vessels. Pediatric and adult congenital teams use 3D echocardiography and cross-sectional studies when anatomy is complex. Equipment selection prioritizes probe versatility, low-radiation protocols and the ability to share reconstructed images across surgical and interventional specialists.
Left atrial appendage closure planning depends on CT or transesophageal measurements of landing zones and device orientation. Circle CVI offers TruPlan tools for appendage assessment, while Philips VeriSight Pro provides 3D intracardiac views during selected interventions. Imaging revenue follows procedural adoption but remains separate from closure-implant sales.
Patients with prosthetic valves require periodic imaging for gradients, leaflet motion, regurgitation and potential thrombosis. A 2025 ACC multisociety consensus discusses CT for prosthetic valve dysfunction, complementing echocardiography. Repeated surveillance supports utilization even when new implant volumes slow, although CT is reserved for selected diagnostic questions.
Valve assessment remains the largest application, while follow-up imaging gains importance as the installed population of transcatheter prostheses ages and redo-procedure planning becomes more frequent.
End-user revenue is classified by the facility that acquires or licenses the imaging product. Hospitals and specialist Heart Valve Centres buy comprehensive imaging suites, while independent imaging practices and ambulatory specialty facilities concentrate on selected outpatient workflows.
Hospitals and Heart Valve Centres represented an estimated ~70% of 2025 revenue. High-volume centers operate echocardiography, CT, MRI and catheter-lab guidance in coordinated Heart Team workflows. The 2025 European guidelines emphasize specialist centers for complex cases, supporting premium imaging purchases but also concentrating demand in fewer institutions.
Independent imaging centers purchase echocardiography and selected cardiac CT or MRI capability for referral-driven diagnosis and follow-up. They compete on appointment access, report turnaround and quality accreditation. Investment in automated measurements and standardized reporting can improve throughput, but these centers typically do not need a full interventional fluoroscopy suite.
Ambulatory specialty facilities account for a smaller share because complex valve interventions still require extensive hospital resources. Selected electrophysiology and appendage-closure pathways can use dedicated imaging equipment and intracardiac catheters. Growth depends on local reimbursement, anesthesia protocols and safety requirements, with facilities purchasing only the imaging functions necessary for their case mix.
Centralization of complex valve treatment should sustain hospital leadership, while outpatient sites expand repeat diagnostic examinations and post-intervention surveillance without matching the capital intensity of tertiary centers.
The product-layer split separates scanner and guidance-system hardware, software sold under distinct licences, and imaging consumables. This prevents a single scanner sale from being duplicated when it includes embedded measurement functions or an associated procedural catheter.
Hardware represented an estimated ~72% of 2025 revenue, including echo consoles, cardiac CT and MRI systems, and attributable fluoroscopy equipment. GE HealthCare, Philips, Siemens Healthineers and Canon Medical compete on image quality, installed service networks and compatibility with clinical workstations. Replacement cycles and large procurement budgets make annual hardware revenue less predictable than procedure volumes.
Software covers separately sold CT sizing, 3D reconstruction, MRI quantification and echo-fluoro fusion modules. Materialise, Circle CVI and Pie Medical Imaging market tools that can support existing scanner fleets. Subscription or workstation licences can expand with heart-team capacity, although compatibility and cybersecurity reviews slow enterprise deployment.
Single-use intracardiac echocardiography catheters and contrast materials contribute revenue when actually used for structural-heart examinations. Philips VeriSight Pro and Bracco Lumason or VueJect illustrate specialized procedural and contrast workflows. Utilization follows patient selection and hospital protocols; reusable probes and standalone therapeutic implants are not classified as consumables here.
Software and procedural imaging consumables should gain relative share through 2034 as planning complexity rises, while hardware remains the largest value pool because scanner and cath-lab platforms require major capital investment.
The regional mix depends on valve-procedure capacity, specialist workforce, health-system reimbursement and installed CT or 4D ultrasound infrastructure. North America leads by value; Europe has mature guideline-driven pathways; Asia-Pacific is expanding specialist imaging capacity.
North America represented an estimated ~43% of 2025 revenue, supported by high imaging-system spending and extensive catheter-based valve programs. The U.S. PREVUE-VALVE study found clinically significant valvular disease in 18.4% of adults aged 65–85 under its broader definition, providing a contemporary indication of potential diagnostic workload. CMS revised TAVR coverage on 10 September 2026, which may change the flow of patients into valve programs and their associated imaging assessments. Canadian centers follow similar Heart Team practices, while equipment purchases depend on provincial funding. GE HealthCare, Philips and Bracco have all introduced cardiac imaging products or clearances affecting the regional supplier mix.
The 2026 CMS TAVR decision adjusted coverage for selected asymptomatic severe aortic stenosis cases and evidence-development requirements. U.S. heart teams use CT sizing and echocardiography before valve procedures, with CT also recommended in the 2025 prosthetic valve imaging consensus. Capital investment is concentrated in specialist hospitals, while outpatient echocardiography supports diagnosis and follow-up. Imaging revenue is distinct from Medicare payment for the implanted valve.
Source: CMS.
Canadian cardiology centers use echocardiography for first-line valve assessment and cross-sectional imaging for complex anatomy. Bracco reported Health Canada authorization for VueJect in August 2026, adding a dedicated ultrasound contrast-delivery option to the market. Adoption depends on provincial procurement and local echo laboratory protocols; catheter-lab products face a smaller pool of eligible centers than routine cardiac ultrasound scanners.
Source: Bracco.
Europe benefits from dense specialist Heart Valve Centre networks and a mature echocardiography workforce. The 2025 ESC/EACTS valvular guidelines expanded discussion of advanced 3D echo, CT and MRI for complex valve disease, supporting multimodality planning. A 2025 Italian registry found substantial valve disease among older adults, reinforcing demand for surveillance imaging. Philips introduced VeriSight Pro 3D ICE in Europe in May 2025 and reported first cases in Germany in June 2025. Materialise and Pie Medical Imaging provide European planning-software expertise, while hospital capital budgets and country-specific reimbursement produce uneven purchasing cycles.
German structural heart programs were among the first European users of Philips VeriSight Pro 3D ICE, with procedures reported at Mainz and Stuttgart in June 2025. Cardiac CT and transesophageal echo remain central to valve planning, and specialized hospitals can integrate catheter-based views into selected procedures. Procurement emphasizes interoperability with established cath-lab systems and training of imaging physicians.
Source: Philips.
The PREVASC registry published in 2025 found moderate or severe valvulopathy in 22.5% of participants aged 75 and older, including aortic stenosis and mitral regurgitation. Italian centers therefore face substantial echo screening and surveillance requirements, while advanced CT supports transcatheter interventions. Budget allocation between diagnostic ultrasound and hybrid procedure suites depends on regional hospital capacity.
Source: PubMed.
Asia-Pacific includes mature imaging markets in Japan and rapidly expanding cardiology infrastructure in China and India. Degenerative valve disease rises with population aging, while rheumatic disease contributes a different case mix in several lower-income settings. FUJIFILM offers the ARIETTA 750SE cardiovascular ultrasound platform, and Mindray supplies cardiology-focused systems that can support broader diagnostic capacity. The 2025 European and American imaging recommendations are useful technical references, but local procurement and reimbursement determine actual adoption. Specialist CT planning is concentrated in larger tertiary hospitals, leaving significant demand for conventional echo outside metropolitan centers.
Japan has a large older population and established cardiac CT and echocardiography infrastructure. FUJIFILM Healthcare markets ARIETTA 750SE with automated cardiovascular measurements, while hospital-based Heart Teams use advanced imaging for complex valve disease. Aging-driven surveillance and the need for reliable operator-independent measurements support ultrasound upgrades; equipment and software uptake remains subject to Japanese regulatory availability and hospital budgets.
Source: FUJIFILM.
An Indian tertiary-center study covering 60,560 echocardiograms identified 3,728 new valve-disease cases, showing the scale of imaging-based case detection in one hospital network. Mindray offers dedicated cardiology ultrasound systems in India, while Canon Medical markets CT TAVR Planning Assist for advanced workups. Cost constraints and specialist shortages favor phased upgrades from basic echo to multimodality planning.
Source: PubMed.
Latin American structural-heart imaging spending is concentrated in tertiary cardiovascular hospitals that perform valve replacement and complex catheter procedures. Echocardiography is the principal first-line modality because it is widely used and does not require ionizing radiation, while CT is reserved for selected anatomical planning. Imported scanner prices, exchange-rate changes and public-sector budgets influence upgrade timing. Specialized software may offer a lower-capital path to improving measurement consistency when suitable CT systems are already installed. The 2025 international valve-imaging consensus supports more structured follow-up, but local accreditation and operator training remain essential. Brazilian procurement decisions also distinguish dedicated echocardiography platforms from CT systems shared with oncology and emergency departments, so supplier revenue cannot be inferred from the number of valve procedures alone. Hospitals with established scanners can add CT measurement modules or advanced probes without purchasing an entirely new imaging platform, while new programs must fund maintenance and technical support.
Brazilian specialist hospitals use echo and CT to evaluate severe aortic stenosis and select patients for transcatheter treatment. International guidance published in 2025 emphasizes multidisciplinary assessment and careful valve anatomy measurement, providing a technical framework for local teams. Scanner procurement is affected by currency exposure and public-private funding differences, so centers may prioritize software upgrades and targeted probe purchases before replacing entire imaging suites.
Source: ESC.
The Middle East and Africa have highly variable access to advanced structural-heart imaging. Gulf hospitals can invest in 4D echocardiography and CT planning platforms, while many African care networks rely on conventional ultrasound and referrals for complex procedures. Workforce training, service contracts and equipment uptime matter alongside scanner acquisition cost. International Heart Team recommendations favor experienced centers for high-complexity interventions, making centralized investment more feasible than distributing specialized imaging systems across low-volume sites. Contrast administration and patient selection also depend on regulatory availability and local protocols. Specialized imaging referrals are particularly important where CT scanner availability is limited outside major cities. A regional heart program may therefore concentrate high-end 3D ultrasound and valve-planning workstations at one referral center while using conventional echo at surrounding hospitals. Software vendors must also provide language-appropriate training, reliable service contracts and integration with existing picture archiving systems before clinical teams can use advanced reconstructions routinely.
UAE tertiary hospitals can deploy high-end cardiac CT and echocardiography for valve procedures, although the regional mix of imaging products depends on institutional contracts. The 2025 ESC/EACTS guidance identifies 3D echocardiography and CT as important tools for complex valve disease; its Heart Team model offers a framework for UAE specialist programs. Local procurement and clinician training remain the main practical adoption constraints.
Source: ESC.
Competition spans large scanner vendors, dedicated procedural imaging providers and specialist cardiac software developers. Purchasers compare image quality, total installed cost, clinical integration and support for specific structural-heart interventions.
GE HealthCare launched Vivid Pioneer with 4D imaging and automation in August 2025. Philips expanded its EPIQ CVx platform and introduced VeriSight Pro 3D intracardiac echocardiography in Europe. These suppliers compete on probe breadth, installed service capability, automated quantification and cath-lab integration rather than on scanner price alone.
Siemens syngo.via supports pre-TAVI cardiac CT planning, while Canon markets CT TAVR Planning Assist with automated workflow tools. Both address procedural sizing and reproducibility, complementing echo-based hemodynamic evaluation. High-end CT hardware and visualization licences are purchased through different capital and operating budgets.
Pie Medical Imaging offers 3mensio Structural Heart for valve and appendage planning. Circle CVI provides cvi42 interventional planning workflows, and Materialise expanded predictive simulation capabilities through the FEops acquisition in July 2024. Their value proposition is workflow specificity and compatibility with existing imaging data.
FUJIFILM and Mindray supply cardiovascular ultrasound systems; Esaote provides ultrasound and 3mensio through its group. Bracco contributes contrast agents and the 2026 VueJect delivery system. Edwards collaborated with Philips on DeviceGuide, illustrating the role of valve-device manufacturers in shaping imaging-guidance requirements without counting valve implants as imaging revenue.
The purchasing process usually separates diagnostic echo upgrades from capital-intensive CT and fluoroscopy systems. Hospital networks may negotiate multi-year maintenance and software agreements, whereas specialist planning tools are licensed per workstation or site. The 2025 ESC/EACTS guidelines reinforce the value of coordinated multimodality assessment, encouraging interoperability across different vendors instead of a single-device approach. Hospitals evaluating 3D intracardiac imaging must also consider catheter cost, anesthesia pathways and operator training.
Partnerships are important where therapy devices require dedicated imaging views. Philips and Edwards collaborated on the DeviceGuide solution cleared in March 2026 for specified mitral repair procedures, while Materialise integrated FEops simulation into its structural-heart planning portfolio. Competitive positioning will depend on evidence for procedural accuracy, integration with clinical reporting and the ability to support both first-time implants and redo interventions. Smaller vendors can compete through specialized measurements without manufacturing full scanners.
September 2026: The Centers for Medicare and Medicaid Services issued an updated TAVR National Coverage Determination on 10 September 2026. The decision changed evidence-development provisions and covered pathways for selected patients with asymptomatic severe aortic stenosis. Imaging teams may see different workup volumes as treatment eligibility and clinical trial requirements evolve, although scanner reimbursement remains separate from the implanted valve. Source
August 2026: Bracco Imaging announced FDA clearance and Health Canada authorization for VueJect, a dedicated ultrasound contrast delivery system intended for cardiology imaging. The company plans initial commercialization in the United States and Canada. Its use with ultrasound-enhancing agents can standardize selected contrast examinations, but it does not replace CT or 3D echo for procedural valve geometry. Source
March 2026: Philips announced U.S. FDA 510(k) clearance for EchoNavigator R5.0 with DeviceGuide, an AI-assisted fusion imaging solution for specified mitral repair workflows. The software combines live 3D ultrasound and fluoroscopy with device tracking, following development work with Edwards Lifesciences. Commercial availability depends on device compatibility and applicable market-release requirements. Source
March 2026: Circle Cardiovascular Imaging expanded its cvi42 platform with advanced vascular CT analysis, integrating technology from Astute Imaging. The company described a unified workflow spanning cardiac, vascular and structural-heart applications. This addition broadens the use of existing image datasets for procedural assessment and reporting rather than requiring a dedicated new scanner for each software capability. Source
August 2025: GE HealthCare launched Vivid Pioneer with 2D and 4D cardiovascular ultrasound, enhanced color flow and automated measurement tools. The company stated that the system had received CE Mark and U.S. FDA 510(k) clearance. Its platform targets diagnostic echo laboratories and interventional imaging workflows, including challenging anatomical assessments and repeated examinations. Source
May 2025: Philips introduced VeriSight Pro 3D intracardiac echocardiography in Europe after earlier U.S. use. The catheter provides real-time imaging from within the heart for selected valve and appendage interventions, potentially avoiding general anesthesia in suitable patients. First European cases were subsequently reported at German hospitals in June 2025. Source
July 2024: Materialise acquired FEops, a Belgian developer of patient-specific structural-heart simulation technology. The acquisition combined Materialise 3D planning tools with predictive analysis of how transcatheter devices interact with individual anatomy. The companies later demonstrated an integrated TAVR planning concept at a November 2025 structural-heart meeting in London. Source
Structural heart imaging revenue is forecast to rise from USD 13.6 billion in 2026 to USD 23.1 billion in 2034, a 6.9% CAGR. Growing valve-disease detection and greater procedural imaging intensity underpin the forecast, with capital budgets limiting the pace of adoption.
| Forecast Variable | 2025–2026 Starting Point | Expected Direction Through 2034 |
|---|---|---|
| Disease detection | 8.2% at least moderate VHD in PREVUE-VALVE | More screening and repeat echo follow-up |
| Guidelines | ESC/EACTS 2025 multimodality emphasis | Broader use of CT and 3D imaging in complex cases |
| Procedure guidance | Philips DeviceGuide clearance in 2026 | More fusion and intracardiac imaging workflows |
| Software planning | Materialise FEops and 3mensio CT tools | Higher attach rate for specialized licences |
| Capital constraints | High-cost CT and hybrid labs | Phased purchases and referral centralization |
| Reimbursement | CMS TAVR coverage update in 2026 | Patient workup mix changes with coverage rules |
North America should retain the largest revenue share because specialist hospitals have extensive imaging fleets and valve-intervention programs. Europe will remain a major market for multimodality planning as the 2025 ESC/EACTS guidance is incorporated into local pathways. Asia-Pacific has opportunities for incremental CT planning and high-end echo deployment as tertiary cardiovascular centers expand, although the pace varies sharply between Japan, China and India.
Growth in echocardiography is likely to come from replacement systems, upgraded 3D probes and repeated examinations rather than a one-time expansion of scanner numbers. Cardiac CT and planning software benefit from more complex valve procedures, especially where operators need reproducible annular and coronary measurements. MRI will remain important for selected functional and tissue-characterization questions but faces longer examination times and limited availability in some health systems.
Interventional guidance may become more specialized as transcatheter mitral and tricuspid procedures expand. Philips DeviceGuide and VeriSight Pro demonstrate distinct approaches: image fusion across platforms and intracardiac visualization from a catheter. Both approaches require dedicated training, compatible equipment and additional per-procedure expenditure. Hospitals will compare clinical benefits with additional equipment expense, and availability of qualified imaging physicians may remain a stronger adoption constraint than technical performance.
By 2034, software licences and dedicated imaging consumables could account for a larger fraction of revenue, while hardware still represents the largest spending category. The 2026 CMS TAVR coverage revision may affect U.S. procedure mix, but no forecast assumes that every additional covered patient triggers a new scanner purchase. Supplier growth depends on installed-base upgrades, workflow integration, service quality and evidence that imaging supports safer or more efficient treatment decisions.
Coverage includes imaging hardware manufacturers, specialized software developers, consumable suppliers and purchasing care settings involved in structural-heart diagnosis and procedural guidance.
The Structural Heart Imaging (SHI) Market is valued at **USD 12.7 billion in 2025** under a defined supplier-revenue boundary covering attributable imaging equipment, dedicated planning software and imaging consumables. It excludes the value of implanted heart valves and hospital treatment services. The 2025 market value uses the published 2024 and 2031 monetary endpoints with a consistent annual growth calculation.
Revenue is projected to grow at a **6.9% CAGR** from 2026 through 2034, reaching **USD 23.1 billion**. Drivers include an older population with valve disease, expanded transcatheter procedures and greater use of CT planning and 3D echocardiography. High CT acquisition costs and limited specialist staffing reduce the speed of procurement in smaller hospitals.
Echocardiography is the largest modality, representing an estimated **~48% of 2025 revenue**. Transthoracic and transesophageal studies are used for diagnosis, severity grading and follow-up, while 3D and intracardiac echo support selected interventions. Cardiac CT is important for pre-TAVR anatomy and device planning.
Cardiac CT provides measurements of the aortic annulus, root, coronary heights and vascular access before transcatheter valve replacement. Specialized software from Siemens, Canon and Pie Medical Imaging helps clinicians interpret these datasets. CT complements echocardiographic assessment of valve function and is not required for every patient.
North America led with an estimated **~43% share of 2025 revenue**, supported by specialist heart centers, extensive imaging fleets and high procedure spending. The United States updated Medicare TAVR coverage in September 2026, potentially affecting patient workups. European demand is supported by the 2025 ESC/EACTS guidance on multimodality imaging for complex valvular disease.
Transesophageal echocardiography images the heart from the esophagus, while intracardiac echocardiography uses a catheter placed within the heart or adjacent vessels. Philips launched VeriSight Pro 3D ICE in Europe in 2025. Catheter-based imaging can avoid general anesthesia in selected cases, but requires vascular access and specialized training.
GE HealthCare, Philips, Siemens Healthineers and Canon Medical supply major imaging platforms. FUJIFILM, Mindray and Esaote provide ultrasound equipment; Pie Medical Imaging, Circle CVI and Materialise supply specialized planning tools. Bracco contributes ultrasound contrast products, and Edwards collaborates on device-specific image guidance.
AI tools can automate cardiac chamber measurements, Doppler workflows, CT segmentation and device alignment. GE Vivid Pioneer and Philips DeviceGuide illustrate commercially available applications announced in 2025 and 2026. Clinicians must still verify results, particularly with complex prosthetic valves or unusual congenital anatomy.
Medicare covers medically necessary imaging under applicable service and coding rules, while TAVR itself is subject to a separate National Coverage Determination. CMS updated that TAVR policy on **10 September 2026**. Coverage for an implanted valve should not be treated as automatic reimbursement for every CT, MRI or ultrasound examination.
High scanner prices, catheter-lab construction costs, staff training, maintenance contracts and software interoperability restrict deployment. Cardiac CT adds radiation and contrast considerations, and intracardiac echo introduces consumable expense. Complex valve programs often centralize procedures at specialist hospitals, leaving smaller centers focused on conventional echocardiography.
The 2034 revenue forecast is **USD 23.1 billion**, with echocardiography remaining the largest modality and planning software gaining importance. Future demand will depend on valve-disease detection, guideline implementation, transcatheter procedure volumes and replacement cycles. Growth is expected to remain uneven across regions because budgets and specialist capacity differ.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.